Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin
Executive Summary
New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval
You may also be interested in...
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
A matter of weeks away from the advisory committee review of the novel obesity drug lorcaserin, Arena's stock is flying high, yet the road to FDA approval, not to mention the daunting market, for obesity drugs looks more uncertain than ever